Clinical trial
A Phase 1, Multicenter, Open-Label, Dose Escalating Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (RHIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML).
NCT02781467 is registered in ClinicalTrials.gov with Celularity Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter, Open-Label, Dose Escalating Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (RHIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML).
- Lead sponsor
- Celularity Incorporated
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- July 11, 2016
- Completion date
- December 7, 2017
- Enrollment
- 10 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.